On the recordNovember 16, 2015
And Mr. Balto also argued that PBMs exclusivity arrangements with some drug manufacturers can keep drug prices artificially high by keeping lower-price drugs off the market and by incentivizing PBMs through manufacturer rebates to switch patients from prescribed drugs to more expensive alternatives.
Source
congress.gov




